| SciPort RLP

2014 - 2016

COMBO DTS.de Register

Univ.-Prof. Dr. TommasoGori

2014 - 2017

A Randomized, Open-label, Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma (#516)

PD Dr. MarkusMunder

2014 - 2017

Forschungszentrum Immunologie (FZI), Asthma Core Facility CF1

PD Dr. MStassen

2014 - 2016

Direct Flow Discover Register

Univ.-Prof. Dr. UlrichHink

2014 - 2019

Pomalidomid/Dexamethason und remissionsabhängig Cyclophosphamid bei Myelom-Rezidiv (#550)

PD Dr. MarkusMunder

2014 - 2017

Forschungszentrum Immunologie (FZI), Core Facility Massenspektrometrie CF7

Dr. StefanTenzer

2014 - 2021

A randomized, double-blind, placebo-controlled phase 3 study of the Bruton’s Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in combination with either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in subjects with previously treated indolent Non-Hodgkin Lymphoma (iNHL) (#551)

Univ.-Prof. Dr. GeorgHeß

2014 - 2017

Allo-Protect (#552)

Dr. Eva MariaWagner

2014 - 2019

WINGS (#572)

Dr. Charisvon Auer

2014

Die Rolle von PVAT-eNOS und -SIRT1 für Adipositas-bedingte Gefäßdysfunktion

Univ.-Prof. Dr. HuigeLi

Starten Sie Ihre Suche...

Johannes Gutenberg-Universität Mainz